CD155 expression and its clinical significance in non‑small cell lung cancer

Oyama, Rintaro; Kanayama, Masatoshi; Mori, Masataka; Matsumiya, Hiroki; Taira, Akihiro; Shinohara, Shinji; Takenaka, Masaru; Yoneda, Kazue; Kuroda, Koji; Tanaka, Fumihiro

doi:10.3892/ol.2022.13286

Cited by 14 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These articles contained 26 studies that involved 4325 cancer patients. The tumor types explored in these 26 studies included soft tissue sarcoma [ 26 ], hepatocellular carcinoma [ 27 – 30 ], acute myeloid leukemia [ 31 ], pancreatic cancer [ 32 ], cholangiocarcinoma [ 33 ], bladder cancer [ 34 ], lung cancer [ 35 – 38 ], esophageal cancer [ 39 , 40 ], breast cancer [ 41 – 44 ], head and neck squamous cell carcinoma [ 45 , 46 ], gastric cancer [ 47 ], gallbladder cancer [ 48 ], cervical adenocarcinoma [ 49 ], and colorectal cancer [ 50 ]. The study samples ranged from 43 to 444.…”

Section: Resultsmentioning

confidence: 99%

“…B. (2021) [ 37 ] Korea 1998–2020 NS 259 Lung cancer IHC Tissue Optimal cutoff Univariate/multivariate analysis 1.36 (1.01–1.83) 6 Lim S. M. (2021) [ 46 ] Korea 2005–2012 NS 375 Head and neck squamous cell carcinoma IHC Tissue > 23 a Univariate analysis 1.4 (1.03–1.90) 6 Oyama R. (2022) [ 38 ] Japan 2003–2006 NS 96 Lung cancer IHC Tissue Optimal cutoff Univariate analysis 3.74 (1.71–8.15) 8 Jin A. L. (2022) [ 30 ] China 2012–2013 Until 2018 189 Hepatocellular carcinoma IHC Tissue Optimal cutoff Univariate/multivariate analysis 2.87 (1.51–5.45) 8 Murakami D. (2022) [ 50 ] Japan 2013 More than 5 years 100 Colorectal cancer IHC Tissue ≥ ++ a Univariate analysis 2.17 (1.12–4.21) 7 a Scores were based on the multiplication or sum of intensity and distribution scores; IHC Immunohistochemical, ELISA Enzyme-linked immunosorbent assay, NS Data were not shown, OS Overall survival, HR Hazard ration …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis

Zhang

Liu²,

Zheng

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

Background It has been previously reported that CD155 is often over-expressed in a variety of cancer types. In fact, it is known to be involved in cancer development, and its role in cancer has been widely established. However, clinical and mechanistic studies involving CD155 yielded conflicting results. Thus, the present study aimed to evaluate overall prognostic value of CD155 in cancer patients, using a comprehensive analysis. Methods Online databases were searched, data was collected, and clinical value of CD155 was evaluated by combining hazard ratios (HRs) or odds ratios (ORs). Results The present study involved meta-analysis of 26 previous studies that involved 4325 cancer patients. These studies were obtained from 25 research articles. The results of the study revealed that increased CD155 expression was significantly associated with reduced OS in patients with cancer as compared to low CD155 expression (pooled HR = 1.772, 95% CI = 1.441–2.178, P < 0.001). Furthermore, subgroup analysis demonstrated that the level of CD155 expression was significantly associated with OS in patients with digestive system cancer (pooled HR = 1.570, 95% CI = 1.120–2.201, P = 0.009), hepatobiliary pancreatic cancer (pooled HR = 1.677, 95% CI = 1.037–2.712, P = 0.035), digestive tract cancer (pooled HR = 1.512, 95% CI = 1.016–2.250, P = 0.042), breast cancer (pooled HR = 2.137, 95% CI = 1.448–3.154, P < 0.001), lung cancer (pooled HR = 1.706, 95% CI = 1.193–2.440, P = 0.003), head and neck cancer (pooled HR = 1.470, 95% CI = 1.160–1.862, P = 0.001). Additionally, a significant correlation was observed between enhanced CD155 expression and advanced tumor stage (pooled OR = 1.697, 95% CI = 1.217–2.366, P = 0.002), LN metastasis (pooled OR = 1.953, 95% CI = 1.253–3.046, P = 0.003), and distant metastasis (pooled OR = 2.253, 95% CI = 1.235–4.110, P = 0.008). Conclusion Altogether, the results of the present study revealed that CD155 acted as an independent marker of prognosis in cancer patients, and it could provide a new and strong direction for cancer treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis

Zhang

Liu²,

Zheng

et al. 2022

World J Surg Onc

View full text Add to dashboard Cite

show abstract

“…Despite their durable response, ICI monotherapy has a response rate of at most 20%, leading to the development of combinations of ICIs. Basic research reported good prospects for combination therapy with multiple ICIs 3 , 4 , which has also been proven in clinical studies 5 – 8 . In the phase II CITYSCAPE trial, anti-T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) antibody tiragolumab combined with the PD-L1 inhibitor atezolizumab significantly improved the overall response rate compared to anti-PD-L1 monotherapy (37% vs. 21%) (37% vs. 21%) 9 .…”

Section: Introductionmentioning

confidence: 90%

“…The sections were visualized with DAB + Liquid (Agilent Technologies) and counterstained with Mayer’s hematoxylin. Retrieval of primary antibody and secondary antibody of the remaining IHC were as follows: as described previously 5 , IHC of CD155 was performed with citrate buffer (pH 6.0) at 98 °C for antigen retrieval and mouse anti-CD155 monoclonal antibody (clone B6, Santa Cruz Biotechnology, Texas, US) and Histofine Simple Stain, MAX-PO (Nichirei Bioscience, Tokyo, Japan). The other than these the same as described above.…”

Section: Methodsmentioning

confidence: 99%

Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy

Mori

Kanayama

Kuwata

et al. 2023

Sci Rep

Self Cite

View full text Add to dashboard Cite

We investigated the effect of preoperative therapy for non-small cell lung cancer on programmed death-ligand 1 (PD-L1), programmed death-1 (PD-1), poliovirus receptor (CD155), and T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif (ITIM) domain (TIGIT) expression and prognosis with the cases of 28 patients received preoperative concurrent chemo-radiotherapy (cCRT) and 27 received preoperative drug therapy. The post-treatment PD-L1 expression was higher in cCRT group than in the drug therapy (50.0% vs 5.0%, p = 0.000), whereas that of CD155 did not significantly differ (40.0% vs 60.0%, p = 0.131). The PD-1 expression was not significantly different between the cCRT and drug therapy groups (51.1% vs 42.9%, p = 0.076), while the TIGIT was significantly higher in the cCRT group (41.5% vs 34.0%, p = 0.008). The patients who received cCRT resulted in elevated PD-L1and TIGIT values had a worse prognosis (p = 0.008). The PD-L1 and TIGIT expression after cCRT was significantly higher than after drug treatment. The cCRT population with high expression of both had a significantly poorer prognosis, indicating elevation of PD-L1 and TIGIT after cCRT as a negative prognostic factor. Combination therapy with anti-PD-L1 and anti-TIGIT antibodies after cCRT may contribute to an improved prognosis.

show abstract

“…Overexpression of these ligands on the tumor is usually associated with poorer prognosis for patients: increased tumor expression of CD112 correlates with increased tumor size and stage, in cancers of the gallbladder ( 265 ), colon ( 266 ), ovary ( 267 ), and pancreas ( 268 ). Likewise, tumor overexpression of CD155 is associated with poor prognosis and progression of multiple cancers ( 269 ) including breast cancer ( 270 ), gastric cancer ( 271 ), non-small cell lung cancer ( 272 ), melanoma ( 273 ), colorectal cancer ( 274 ), and sarcoma ( 275 ).…”

Section: Receptor Driven Signaling In Natural Killer Cellsmentioning

confidence: 99%

Killer instincts: natural killer cells as multifactorial cancer immunotherapy

Nersesian,

Carter,

Lee

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Natural killer (NK) cells integrate heterogeneous signals for activation and inhibition using germline-encoded receptors. These receptors are stochastically co-expressed, and their concurrent engagement and signaling can adjust the sensitivity of individual cells to putative targets. Against cancers, which mutate and evolve under therapeutic and immunologic pressure, the diversity for recognition provided by NK cells may be key to comprehensive cancer control. NK cells are already being trialled as adoptive cell therapy and targets for immunotherapeutic agents. However, strategies to leverage their naturally occurring diversity and agility have not yet been developed. In this review, we discuss the receptors and signaling pathways through which signals for activation or inhibition are generated in NK cells, focusing on their roles in cancer and potential as targets for immunotherapies. Finally, we consider the impacts of receptor co-expression and the potential to engage multiple pathways of NK cell reactivity to maximize the scope and strength of antitumor activities.

show abstract

CD155 expression and its clinical significance in non‑small cell lung cancer

Cited by 14 publications

References 23 publications

Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis

Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis

Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy

Killer instincts: natural killer cells as multifactorial cancer immunotherapy

Contact Info

Product

Resources

About